MediciNova's MN-166 can reduce retinal thinning in progressive MS

 

• MediciNova (NASDAQ:MNOV) announces that positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) were published in Multiple Sclerosis Journal. OCT was a secondary outcome measure in the trial.
• The authors conclude that retinal thinning in MS may be attenuated by MN-166 (ibudilast) and that sample size estimates suggest OCT can be a viable outcome measure in progressive MS trials if a therapy has a large treatment effect.
• 183 participants were imaged with Cirrus and 61 participants with Spectralis.
• All OCT measures showed less loss of retinal tissue for MN-166 compared to placebo. Key results included:
• Change in pRNFL (peripapillary retinal nerve fiber layer) thickness was +0.0424 uM/year for MN166 versus −0.2630 uM/year for placebo (n = 244, p = 0.22).
• Macular volume change was −0.00503 mm³/year for MN-166 versus −0.03659 mm³/year for placebo in the Spectralis cohort (n = 61, p = 0.044).
• For the Cirrus cohort, macular volume change was −0.00040 mm³/year for MN-166 (ibudilast) compared to −0.02083 mm³/year for placebo (n = 183, p = 0.1734).
• Ganglion cell-inner plexiform layer thickness change, available from Cirrus, was −0.4893 uM/year for MN-166 (ibudilast) versus −0.9587 uM/year for placebo (n = 183, p = 0.12).
• https://seekingalpha.com/news/3639336-medicinovas-mnminus-166-can-reduce-retinal-thinning-in-progressive-multiple-sclerosis